个人中心 - 老虎社区

大耳朵Ears

IP属地：山东

帖子 · 25帖子 · 25
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- 大耳朵Ears大耳朵Ears
  ·07-30
  $特斯拉(TSLA)$ 持股体验犹如过山车
  1,202 评论
  1
  分享
  举报
- 大耳朵Ears大耳朵Ears
  ·07-16
  绝对赞同
  863 评论
  1
  分享
  举报
- 大耳朵Ears大耳朵Ears
  ·06-25
  $特斯拉(TSLA)$ 扶我青云志，会当凌绝顶剑指 688
  2,632 1
  2
  分享
  举报
- 大耳朵Ears大耳朵Ears
  ·05-26
  医药股大批低位低估的，药明、百济
  港股医药股为什么涨疯了？
  智通财经APP获悉，近期，港股医药股迎来爆发式上涨，尤其是创新药板块表现尤为亮眼。港股医药股的强势崛起，本质是技术突破、估值修复、资金共振的三重驱动。相关的公司若披露一些超预期的药物临床数据，也将继续推动相关公司股价上涨。二季度以来，港股通创新药 ETF 净流入
  港股医药股为什么涨疯了？
  1,187 评论
  1
  分享
  举报
- 大耳朵Ears大耳朵Ears
  ·05-21
  恒瑞不是，百济和药明是
  745 评论
  1
  分享
  举报
- 大耳朵Ears大耳朵Ears
  ·04-28
  $特斯拉(TSLA)$ 看来还是不到时候，散了吧
  960 评论
  3
  分享
  举报
- 大耳朵Ears大耳朵Ears
  ·04-28
  $特斯拉(TSLA)$ 今天很关键
  1,513 1
  2
  分享
  举报
- 大耳朵Ears大耳朵Ears
  ·04-21
  人家全职当然限制，你要啥啥没有
  美团再发声：与其造谣引流不如兑现承诺，此前辟谣“二选一”
  没有任何理由对某平台进行任何限制。
  美团再发声：与其造谣引流不如兑现承诺，此前辟谣“二选一”
  988 评论
  4
  分享
  举报
- 大耳朵Ears大耳朵Ears
  ·03-18
  短期受政治因素扰动风险，长期绝佳机会
  1,355 评论
  点赞
  分享
  举报
- 大耳朵Ears大耳朵Ears
  ·03-12
  绝对的好机会
  1,122 评论
  点赞
  分享
  举报
暂无粉丝

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3506509089469805","uuid":"3506509089469805","gmtCreate":1543415067789,"gmtModify":1673016716875,"name":"大耳朵Ears","pinyin":"dedearsdaerduoears","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/b2f85cc68cf636aa2ce111d8b2ebe575","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":7,"headSize":39,"tweetSize":25,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":6,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.05.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"45aa8c9032204ad8bee19bb27da4edb8-1","templateUuid":"45aa8c9032204ad8bee19bb27da4edb8","name":"交易笔数","description":"累计达100笔","bigImgUrl":"https://static.tigerbbs.com/f6040a65e0c6e125e4dcfe0101de45ee","smallImgUrl":"https://static.tigerbbs.com/f803dba33fef1aa87b64be09f4f064ee","grayImgUrl":"https://static.tigerbbs.com/5dfa45d4a1e98a2d8c2e1b4253ddd916","redirectLinkEnabled":0,"redirectLink":"https://www.itigerup.com/activity/market/2023/stock-contest?adcode=StockContest2023","hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.04.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":5100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.26","exceedPercentage":"93.33%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.23","exceedPercentage":"80.29%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"754899bf0917479fa68cfac1ea371651-5","templateUuid":"754899bf0917479fa68cfac1ea371651","name":"月赛Top 10团队成员","description":"Top 10","bigImgUrl":"https://static.tigerbbs.com/dcb8ba4e1efd99be2b948dc3b81abfa8","smallImgUrl":"https://static.tigerbbs.com/a4aa0d1bc9d709e9af2662788ca5d144","grayImgUrl":"https://static.tigerbbs.com/5704f3dcb758b5392763b7709ebf548a","redirectLinkEnabled":0,"redirectLink":"https://www.tigerbrokers.com.sg/activity/market/2023/stock-contest?adcode=StockContest2023","hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":5400},{"badgeId":"d5d1b81d9a9a4306a42a1560851c3454-3","templateUuid":"d5d1b81d9a9a4306a42a1560851c3454","name":"实盘挑战","description":"累计达6个月","bigImgUrl":"https://static.tigerbbs.com/9fec469914e1280bf4801f36539f41fd","smallImgUrl":"https://static.tigerbbs.com/890d6c2bdab9dd1b255a1e7e9ae2264f","grayImgUrl":"https://static.tigerbbs.com/aeea12778e0c2c686984e1efc3ed8fd4","redirectLinkEnabled":0,"redirectLink":"https://www.tigerbrokers.com.sg/activity/market/2023/stock-contest?adcode=StockContest2023","hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.03","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":5600},{"badgeId":"5697d37f217342faaa027fdb5a6e7c12-4","templateUuid":"5697d37f217342faaa027fdb5a6e7c12","name":"单笔平均盈利排行","description":"Top 10%","bigImgUrl":"https://static.tigerbbs.com/5d4a486b5707ca641782b8afa4d3261e","smallImgUrl":"https://static.tigerbbs.com/9d61ed9b62f2e13f9335a3de3bd18529","grayImgUrl":"https://static.tigerbbs.com/320fb40401f70873e9d982813fe82344","redirectLinkEnabled":0,"redirectLink":"https://www.itigerup.com/activity/market/2023/stock-contest?adcode=StockContest2023","hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.08","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":5200},{"badgeId":"1f74612b6f95455f970edd02b5316db8-6","templateUuid":"1f74612b6f95455f970edd02b5316db8","name":"收益排行","description":"Top 3%","bigImgUrl":"https://static.tigerbbs.com/6fbaa8e552e02eae8e6a2ce5d6566431","smallImgUrl":"https://static.tigerbbs.com/98862e418516dab972bed7aaf561dec6","grayImgUrl":"https://static.tigerbbs.com/3a5ca933a5695ed2e862b228f6c09ee5","redirectLinkEnabled":0,"redirectLink":"https://www.itigerup.com/activity/market/2023/stock-contest?adcode=StockContest2023","hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.09.08","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":5300},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.08.19","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.02.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":10,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":7,"crmLevelSwitch":1,"location":"山东","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":7,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":462294122009048,"gmtCreate":1753883713971,"gmtModify":1753883717391,"author":{"id":"3506509089469805","authorId":"3506509089469805","name":"大耳朵Ears","avatar":"https://static.tigerbbs.com/b2f85cc68cf636aa2ce111d8b2ebe575","crmLevel":7,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3506509089469805","authorIdStr":"3506509089469805"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$&nbsp;</a><v-v data-views=\"1\"></v-v> 持股体验犹如过山车","listText":"<a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$&nbsp;</a><v-v data-views=\"1\"></v-v> 持股体验犹如过山车","text":"$特斯拉(TSLA)$ 持股体验犹如过山车","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/462294122009048","isVote":1,"tweetType":1,"viewCount":1202,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":457102774235344,"gmtCreate":1752634445627,"gmtModify":1752634446860,"author":{"id":"3506509089469805","authorId":"3506509089469805","name":"大耳朵Ears","avatar":"https://static.tigerbbs.com/b2f85cc68cf636aa2ce111d8b2ebe575","crmLevel":7,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3506509089469805","authorIdStr":"3506509089469805"},"themes":[],"htmlText":"绝对赞同","listText":"绝对赞同","text":"绝对赞同","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/457102774235344","isVote":1,"tweetType":1,"viewCount":863,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":449713030210032,"gmtCreate":1750820102586,"gmtModify":1750820103842,"author":{"id":"3506509089469805","authorId":"3506509089469805","name":"大耳朵Ears","avatar":"https://static.tigerbbs.com/b2f85cc68cf636aa2ce111d8b2ebe575","crmLevel":7,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3506509089469805","authorIdStr":"3506509089469805"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$&nbsp;</a> 扶我青云志，会当凌绝顶剑指 688","listText":"<a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$&nbsp;</a> 扶我青云志，会当凌绝顶剑指 688","text":"$特斯拉(TSLA)$ 扶我青云志，会当凌绝顶剑指 688","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/449713030210032","isVote":1,"tweetType":1,"viewCount":2632,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":439244431499600,"gmtCreate":1748256270585,"gmtModify":1748256271842,"author":{"id":"3506509089469805","authorId":"3506509089469805","name":"大耳朵Ears","avatar":"https://static.tigerbbs.com/b2f85cc68cf636aa2ce111d8b2ebe575","crmLevel":7,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3506509089469805","authorIdStr":"3506509089469805"},"themes":[],"htmlText":"医药股大批低位低估的，药明、百济","listText":"医药股大批低位低估的，药明、百济","text":"医药股大批低位低估的，药明、百济","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/439244431499600","repostId":"2538174343","repostType":2,"repost":{"id":"2538174343","kind":"news","pubTimestamp":1748252790,"share":"https://www.laohu8.com/m/news/2538174343?lang=&edition=full","pubTime":"2025-05-26 17:46","market":"hk","language":"zh","title":"港股医药股为什么涨疯了？","url":"https://stock-news.laohu8.com/highlight/detail?id=2538174343","media":"智通财经","summary":"智通财经APP获悉，近期，港股医药股迎来爆发式上涨，尤其是创新药板块表现尤为亮眼。港股医药股的强势崛起，本质是技术突破、估值修复、资金共振的三重驱动。相关的公司若披露一些超预期的药物临床数据，也将继续推动相关公司股价上涨。二季度以来，港股通创新药 ETF 净流入","content":"<html><head></head><body><p>智通财经APP获悉，近期，港股医药股迎来爆发式上涨，尤其是创新药板块表现尤为亮眼。<strong>港股医药股的强势崛起，本质是技术突破、估值修复、资金共振的三重驱动。</strong>创新药国际化验证了 “中国智造” 的含金量，历史低位的估值提供了安全垫，而资金配置的升级则打开了上行空间。<strong>随着 ASCO 年会等行业事件的催化，以及政策红利的持续释放，港股医药板块有望在 “估值修复 + 成长” 的双重逻辑下延续强势表现。</strong></p><p>随着<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>和<a href=\"https://laohu8.com/S/01530\">三生制药</a>合作的重磅协议披露，辉瑞支付12.5亿美元首付款及最高48亿美元里程碑费用，激发市场对国产创新药出海能力的信心。三生制药5月20日最高涨幅超过40%，最终收涨32%。类似案例还包括 <a href=\"https://laohu8.com/S/01276\">恒瑞医药</a> 、<a href=\"https://laohu8.com/S/09926\">康方生物</a>等企业的授权合作，也验证了国内创新药的国际竞争力。</p><p>不仅如此，创新药板块同时还处于低估值以及内外资从极低配置提高的过程。实际上在三生制药的大合同披露前1个月，恒生医疗保健指数涨幅已经接近20%，在三生的合同之后，吸引了更多的关注，推动该指数延续上涨4%。如果复盘医药板块的表现，包括<a href=\"https://laohu8.com/S/01801\">信达生物</a>，康方生物等，随着药物试验的进展，年内最多也有翻倍涨幅。</p><p><strong>一、创新药出海破局，研发实力获全球认可</strong></p><p>中国药企正从 “仿制跟随” 向 “创新主导” 加速转型，一系列国际授权合作便是最好的证明。2025 年以来，多个重磅合作协议接连落地：</p><p>5 月 20 日，三生制药将 PD-1/VEGF 双抗药物 SSGJ-707 的全球开发权以 12.5 亿美元首付款 + 48 亿美元里程碑费用授权给辉瑞，刷新国内创新药出海首付款纪录；</p><p>3 月 24 日，<a href=\"https://laohu8.com/S/03933\">联邦制药</a>与<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>签订协议，授权 GLP-1/GIP/GCGR 三重激动剂 UBT251 的全球权益（除中国大陆及港澳台地区），首付款 2 亿美元，潜在里程碑付款 18 亿美元，另加销售分成；</p><p>3 月 21 日，和铂医药与<a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>共同开发多特异性抗体疗法，覆盖免疫疾病和肿瘤领域；首付款1.75亿美元，最高44亿美元里程碑付款，总金额达 45.75 亿美元（含 1.05 亿美元股权投资）；</p><p>3 月 26 日，<a href=\"https://laohu8.com/S/01276\">恒瑞医药</a>与<a href=\"https://laohu8.com/S/MRK\">默沙东</a>合作，默沙东支付 2 亿美元首付款，总里程碑金额 17.7 亿美元。</p><p>中国创新药海外授权交易增长趋势的背后，是中国药企从“仿制跟随”向“创新主导”的转型，背后是极致的内卷带来竞争力的提升，比如中国创新药研发成本仅为美国的1/3，临床试验周期缩短30%。德琪医药成立AI部门后，其卵巢癌药物研发周期缩短40%科济药业借助AI优化CAR-T细胞疗法，临床试验患者应答率提升至78%。</p><p>CAR-T、ADC（抗体偶联药物）、双抗等前沿领域，中国已涌现多个“同类最优”产品。<a href=\"https://laohu8.com/S/GLW\">康宁</a>杰瑞的双抗平台、科伦博泰的ADC技术、和铂医药的全人源抗体平台，这些“硬核科技”正在打破跨国药企的技术垄断。以加科思的KRAS抑制剂为例，其客观缓解率达77.7%，较<a href=\"https://laohu8.com/S/AMGN\">安进</a>同类产品高出15个百分点。</p><p>这些案例不仅验证了国内创新药的国际竞争力，更标志着中国药企研发能力已跻身全球第一梯队。</p><p><strong>二、即将到来2025年ASCO年会，爆点预期多多</strong></p><p>5月30日至6月3日将会在美国举办2025年ASCO年会，今年会议涵盖500余项口头报告及2700余份壁报，覆盖肿瘤学各领域前沿进展，中国学者共有71项原创研究入选口头报告环节，包括信达生物、<a href=\"https://laohu8.com/S/ONC\">百济神州</a>、恒瑞医药等企业的创新药物数据。相关的公司若披露一些超预期的药物临床数据，也将继续推动相关公司股价上涨。</p><p>根据国盛医药发布的ASCO摘要点评，</p><p>Ø映恩生物的B7H3 ADC 前列腺癌数据超预期（PFS 8.3 个月持续延长，接近<a href=\"https://laohu8.com/S/NVS\">诺华</a>核药）</p><p>Ø信达生物：1）肺癌：3mk/km 组疗效信号非常明显，尤其鳞癌三线患者 PFS7.3 个月，腺癌中位 PFS 4.2 月 2）结直肠癌：OS 转化率很高，单药治疗的中位 OS 为 16.1 个月，联合治疗的中位 OS 未成熟。</p><p>Ø <a href=\"https://laohu8.com/S/688062\">迈威生物</a> ：Nectin4 ADC、B7H3 ADC、TROP2 ADC 均有亮眼数据，尤其是B7H3 ADC 的前列腺癌的 ORR，以及 TROP2 ADC 在子宫内膜癌、胃癌、HR + 乳腺癌的 ORR 都比较高。</p><p>Ø<a href=\"https://laohu8.com/S/01177\">中国生物制药</a>：安罗加PD-L1 头对头替雷利珠的一线鳞癌三期，取得mPFS 10.12 个月，疾病进展 / 死亡风险降低 36% 的显著优效。</p><p>除了以上公司之外，<a href=\"https://laohu8.com/S/688266\">泽璟制药</a>，科伦博泰，<a href=\"https://laohu8.com/S/ZLAB\">再鼎医药</a>，<a href=\"https://laohu8.com/S/02696\">复宏汉霖</a>，科济药业也公布了其核心产品数据。</p><p><strong>三、低估值提供安全垫，价值回归需求强烈</strong></p><p>截至 2025 年 5 月，港股医药行业平均市盈率仅 15 倍，远低于 A 股的 24 倍和美股的 24 倍。其中，仿制药远期 PE 约 14 倍，接近历史低位；创新药经历上涨后 PE 仍仅 20 倍，相比美股 Biotech 公司 50 倍以上的估值，性价比显著。</p><p>从市场表现看，恒生医疗保健指数自 2021 年高点回撤超 60%，部分个股甚至跌破净资产，当前估值分位数处于近 3 年的 10% 以下，安全边际显著。</p><p>以<a href=\"https://laohu8.com/S/01093\">石药集团</a>为例：</p><p>其静态PE仅16倍，远低于行业平均水平。实际上公司的创新药平台也进入兑现期，新型EGFR ADC有望破局肺癌EGFR-TKI耐药；多个创新管线达成对外授权成为新增长点。例如，SYS6010在‌EGFR-TKI耐药NSCLC患者‌中展现出高缓解率：</p><p>1）新型EGFR ADC（SYS6010）‌I期临床结果优秀，在102例EGFR突变非鳞NSCLC患者中，ORR为39.2%，DCR达93.1%；</p><p>其中单纯EGFR-TKI耐药的EGFR敏感突变非鳞NSCLC（n=19）：ORR高达63.2%，DCR为94.7%；</p><p>而EGFR-TKI和含铂化疗双耐药的EGFR敏感突变非鳞NSCLC（n=78）：ORR 为33.3%，DCR为92.3%。</p><p>2）2024年8月26日启动了SYS6010联合奥希替尼一线治疗EGFR突变型局部晚期或转移性NSCLC的Ib/III期临床研究。</p><p>而且公司还有其他大品种会有大适应症的扩容，存在业绩极大改善的预期。</p><p><strong>四、政策红利释放，行业生态持续优化</strong></p><p>政策方面的压力明显减少，集采影响钝化，创新药纳入医保后加速放量，企业盈利明显提升，尤其是医保谈判对于有真正创新能力的药物给予了超出市场极端悲观预期的利润率水平。</p><p>最新医疗器械集采中，国产替代产品获得15%溢价，创新药医保谈判降价幅度收窄至30%以内。这种“优质优价”的规则重塑，使头部药企的研发投入获得正向反馈。</p><p>2025年政府工作报告首提“制定创新药目录”，意味着高临床价值但未纳入医保的创新药，将通过商业保险、专项基金等新渠道获得支付支持。据测算，这一政策将释放超3000亿元市场空间，直接利好如<a href=\"https://laohu8.com/S/688235\">百济神州</a>PD-1抑制剂等前沿疗法。医保局人士透露，首个目录或于三季度发布，涵盖20-30个重磅品种。</p><p>商务部《稳外资行动方案》明确支持生物医药分段生产试点，为药企跨国合作扫清障碍。政策催化下，2025年前四月中国创新药跨境交易额同比激增180%，三生制药与辉瑞60.5亿美元的“世纪交易”更创下首付款纪录。这种“国家队”式的政策护航，使中国药企在全球产业链中的地位发生质变。</p><p><strong>五、资金共振驱动，配置逻辑转向 “估值修复 + 成长双击”</strong></p><p>在低估值、高增长预期下，资金持续涌入港股医药板块。二季度以来，港股通创新药 ETF 净流入超 50 亿元，份额创历史新高；截至 5 月 23 日，香港医药 ETF 年内涨幅超 25%，规模突破 70 亿元。</p><p>机构方面，主动型医药基金普遍增持港股，长城医药产业精选 A、永赢医药创新智选等基金重仓港股医药股，业绩表现优异。外资方面，随着美国市场动荡，国际对冲基金对港股医药板块的配置比例从 2% 飙升至 7%。</p><p>此外，行业并购活跃，MNC 巨头溢价收购中国管线、上市药企分拆高成长业务等资本运作，形成 “价值发现 - 资本运作 - 估值提升” 的正向循环。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股医药股为什么涨疯了？</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股医药股为什么涨疯了？\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-26 17:46 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1297573.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，近期，港股医药股迎来爆发式上涨，尤其是创新药板块表现尤为亮眼。港股医药股的强势崛起，本质是技术突破、估值修复、资金共振的三重驱动。创新药国际化验证了 “中国智造” 的含金量，历史低位的估值提供了安全垫，而资金配置的升级则打开了上行空间。随着 ASCO 年会等行业事件的催化，以及政策红利的持续释放，港股医药板块有望在 “估值修复 + 成长” 的双重逻辑下延续强势表现。随着辉瑞和...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1297573.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","relate_stocks":{"159718":"港股医药"},"source_url":"http://www.zhitongcaijing.com/content/detail/1297573.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2538174343","content_text":"智通财经APP获悉，近期，港股医药股迎来爆发式上涨，尤其是创新药板块表现尤为亮眼。港股医药股的强势崛起，本质是技术突破、估值修复、资金共振的三重驱动。创新药国际化验证了 “中国智造” 的含金量，历史低位的估值提供了安全垫，而资金配置的升级则打开了上行空间。随着 ASCO 年会等行业事件的催化，以及政策红利的持续释放，港股医药板块有望在 “估值修复 + 成长” 的双重逻辑下延续强势表现。随着辉瑞和三生制药合作的重磅协议披露，辉瑞支付12.5亿美元首付款及最高48亿美元里程碑费用，激发市场对国产创新药出海能力的信心。三生制药5月20日最高涨幅超过40%，最终收涨32%。类似案例还包括 恒瑞医药 、康方生物等企业的授权合作，也验证了国内创新药的国际竞争力。不仅如此，创新药板块同时还处于低估值以及内外资从极低配置提高的过程。实际上在三生制药的大合同披露前1个月，恒生医疗保健指数涨幅已经接近20%，在三生的合同之后，吸引了更多的关注，推动该指数延续上涨4%。如果复盘医药板块的表现，包括信达生物，康方生物等，随着药物试验的进展，年内最多也有翻倍涨幅。一、创新药出海破局，研发实力获全球认可中国药企正从 “仿制跟随” 向 “创新主导” 加速转型，一系列国际授权合作便是最好的证明。2025 年以来，多个重磅合作协议接连落地：5 月 20 日，三生制药将 PD-1/VEGF 双抗药物 SSGJ-707 的全球开发权以 12.5 亿美元首付款 + 48 亿美元里程碑费用授权给辉瑞，刷新国内创新药出海首付款纪录；3 月 24 日，联邦制药与诺和诺德签订协议，授权 GLP-1/GIP/GCGR 三重激动剂 UBT251 的全球权益（除中国大陆及港澳台地区），首付款 2 亿美元，潜在里程碑付款 18 亿美元，另加销售分成；3 月 21 日，和铂医药与阿斯利康共同开发多特异性抗体疗法，覆盖免疫疾病和肿瘤领域；首付款1.75亿美元，最高44亿美元里程碑付款，总金额达 45.75 亿美元（含 1.05 亿美元股权投资）；3 月 26 日，恒瑞医药与默沙东合作，默沙东支付 2 亿美元首付款，总里程碑金额 17.7 亿美元。中国创新药海外授权交易增长趋势的背后，是中国药企从“仿制跟随”向“创新主导”的转型，背后是极致的内卷带来竞争力的提升，比如中国创新药研发成本仅为美国的1/3，临床试验周期缩短30%。德琪医药成立AI部门后，其卵巢癌药物研发周期缩短40%科济药业借助AI优化CAR-T细胞疗法，临床试验患者应答率提升至78%。CAR-T、ADC（抗体偶联药物）、双抗等前沿领域，中国已涌现多个“同类最优”产品。康宁杰瑞的双抗平台、科伦博泰的ADC技术、和铂医药的全人源抗体平台，这些“硬核科技”正在打破跨国药企的技术垄断。以加科思的KRAS抑制剂为例，其客观缓解率达77.7%，较安进同类产品高出15个百分点。这些案例不仅验证了国内创新药的国际竞争力，更标志着中国药企研发能力已跻身全球第一梯队。二、即将到来2025年ASCO年会，爆点预期多多5月30日至6月3日将会在美国举办2025年ASCO年会，今年会议涵盖500余项口头报告及2700余份壁报，覆盖肿瘤学各领域前沿进展，中国学者共有71项原创研究入选口头报告环节，包括信达生物、百济神州、恒瑞医药等企业的创新药物数据。相关的公司若披露一些超预期的药物临床数据，也将继续推动相关公司股价上涨。根据国盛医药发布的ASCO摘要点评，Ø映恩生物的B7H3 ADC 前列腺癌数据超预期（PFS 8.3 个月持续延长，接近诺华核药）Ø信达生物：1）肺癌：3mk/km 组疗效信号非常明显，尤其鳞癌三线患者 PFS7.3 个月，腺癌中位 PFS 4.2 月 2）结直肠癌：OS 转化率很高，单药治疗的中位 OS 为 16.1 个月，联合治疗的中位 OS 未成熟。Ø 迈威生物 ：Nectin4 ADC、B7H3 ADC、TROP2 ADC 均有亮眼数据，尤其是B7H3 ADC 的前列腺癌的 ORR，以及 TROP2 ADC 在子宫内膜癌、胃癌、HR + 乳腺癌的 ORR 都比较高。Ø中国生物制药：安罗加PD-L1 头对头替雷利珠的一线鳞癌三期，取得mPFS 10.12 个月，疾病进展 / 死亡风险降低 36% 的显著优效。除了以上公司之外，泽璟制药，科伦博泰，再鼎医药，复宏汉霖，科济药业也公布了其核心产品数据。三、低估值提供安全垫，价值回归需求强烈截至 2025 年 5 月，港股医药行业平均市盈率仅 15 倍，远低于 A 股的 24 倍和美股的 24 倍。其中，仿制药远期 PE 约 14 倍，接近历史低位；创新药经历上涨后 PE 仍仅 20 倍，相比美股 Biotech 公司 50 倍以上的估值，性价比显著。从市场表现看，恒生医疗保健指数自 2021 年高点回撤超 60%，部分个股甚至跌破净资产，当前估值分位数处于近 3 年的 10% 以下，安全边际显著。以石药集团为例：其静态PE仅16倍，远低于行业平均水平。实际上公司的创新药平台也进入兑现期，新型EGFR ADC有望破局肺癌EGFR-TKI耐药；多个创新管线达成对外授权成为新增长点。例如，SYS6010在‌EGFR-TKI耐药NSCLC患者‌中展现出高缓解率：1）新型EGFR ADC（SYS6010）‌I期临床结果优秀，在102例EGFR突变非鳞NSCLC患者中，ORR为39.2%，DCR达93.1%；其中单纯EGFR-TKI耐药的EGFR敏感突变非鳞NSCLC（n=19）：ORR高达63.2%，DCR为94.7%；而EGFR-TKI和含铂化疗双耐药的EGFR敏感突变非鳞NSCLC（n=78）：ORR 为33.3%，DCR为92.3%。2）2024年8月26日启动了SYS6010联合奥希替尼一线治疗EGFR突变型局部晚期或转移性NSCLC的Ib/III期临床研究。而且公司还有其他大品种会有大适应症的扩容，存在业绩极大改善的预期。四、政策红利释放，行业生态持续优化政策方面的压力明显减少，集采影响钝化，创新药纳入医保后加速放量，企业盈利明显提升，尤其是医保谈判对于有真正创新能力的药物给予了超出市场极端悲观预期的利润率水平。最新医疗器械集采中，国产替代产品获得15%溢价，创新药医保谈判降价幅度收窄至30%以内。这种“优质优价”的规则重塑，使头部药企的研发投入获得正向反馈。2025年政府工作报告首提“制定创新药目录”，意味着高临床价值但未纳入医保的创新药，将通过商业保险、专项基金等新渠道获得支付支持。据测算，这一政策将释放超3000亿元市场空间，直接利好如百济神州PD-1抑制剂等前沿疗法。医保局人士透露，首个目录或于三季度发布，涵盖20-30个重磅品种。商务部《稳外资行动方案》明确支持生物医药分段生产试点，为药企跨国合作扫清障碍。政策催化下，2025年前四月中国创新药跨境交易额同比激增180%，三生制药与辉瑞60.5亿美元的“世纪交易”更创下首付款纪录。这种“国家队”式的政策护航，使中国药企在全球产业链中的地位发生质变。五、资金共振驱动，配置逻辑转向 “估值修复 + 成长双击”在低估值、高增长预期下，资金持续涌入港股医药板块。二季度以来，港股通创新药 ETF 净流入超 50 亿元，份额创历史新高；截至 5 月 23 日，香港医药 ETF 年内涨幅超 25%，规模突破 70 亿元。机构方面，主动型医药基金普遍增持港股，长城医药产业精选 A、永赢医药创新智选等基金重仓港股医药股，业绩表现优异。外资方面，随着美国市场动荡，国际对冲基金对港股医药板块的配置比例从 2% 飙升至 7%。此外，行业并购活跃，MNC 巨头溢价收购中国管线、上市药企分拆高成长业务等资本运作，形成 “价值发现 - 资本运作 - 估值提升” 的正向循环。","news_type":1,"symbols_score_info":{"159718":1}},"isVote":1,"tweetType":1,"viewCount":1187,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":437433713308216,"gmtCreate":1747825999459,"gmtModify":1747826001496,"author":{"id":"3506509089469805","authorId":"3506509089469805","name":"大耳朵Ears","avatar":"https://static.tigerbbs.com/b2f85cc68cf636aa2ce111d8b2ebe575","crmLevel":7,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3506509089469805","authorIdStr":"3506509089469805"},"themes":[],"htmlText":"恒瑞不是，百济和药明是","listText":"恒瑞不是，百济和药明是","text":"恒瑞不是，百济和药明是","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/437433713308216","isVote":1,"tweetType":1,"viewCount":745,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":429386844647760,"gmtCreate":1745852744681,"gmtModify":1745852746161,"author":{"id":"3506509089469805","authorId":"3506509089469805","name":"大耳朵Ears","avatar":"https://static.tigerbbs.com/b2f85cc68cf636aa2ce111d8b2ebe575","crmLevel":7,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3506509089469805","authorIdStr":"3506509089469805"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$&nbsp;</a> 看来还是不到时候，散了吧","listText":"<a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$&nbsp;</a> 看来还是不到时候，散了吧","text":"$特斯拉(TSLA)$ 看来还是不到时候，散了吧","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/429386844647760","isVote":1,"tweetType":1,"viewCount":960,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":429366352630448,"gmtCreate":1745847658316,"gmtModify":1745847660891,"author":{"id":"3506509089469805","authorId":"3506509089469805","name":"大耳朵Ears","avatar":"https://static.tigerbbs.com/b2f85cc68cf636aa2ce111d8b2ebe575","crmLevel":7,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3506509089469805","authorIdStr":"3506509089469805"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$&nbsp;</a> 今天很关键","listText":"<a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$&nbsp;</a> 今天很关键","text":"$特斯拉(TSLA)$ 今天很关键","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/429366352630448","isVote":1,"tweetType":1,"viewCount":1513,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":426868650316152,"gmtCreate":1745239716908,"gmtModify":1745239718725,"author":{"id":"3506509089469805","authorId":"3506509089469805","name":"大耳朵Ears","avatar":"https://static.tigerbbs.com/b2f85cc68cf636aa2ce111d8b2ebe575","crmLevel":7,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3506509089469805","authorIdStr":"3506509089469805"},"themes":[],"htmlText":"人家全职当然限制，你要啥啥没有","listText":"人家全职当然限制，你要啥啥没有","text":"人家全职当然限制，你要啥啥没有","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/426868650316152","repostId":"1110612549","repostType":2,"repost":{"id":"1110612549","kind":"news","pubTimestamp":1745234530,"share":"https://www.laohu8.com/m/news/1110612549?lang=&edition=full","pubTime":"2025-04-21 19:22","market":"hk","language":"zh","title":"美团再发声：与其造谣引流不如兑现承诺，此前辟谣“二选一”","url":"https://stock-news.laohu8.com/highlight/detail?id=1110612549","media":"新浪科技","summary":"没有任何理由对某平台进行任何限制。","content":"<html><head></head><body><p style=\"text-align: start;\">周一晚间消息，美团官方公众号今晚发声：“与其造谣引流，不如兑现承诺”，并配文：“他强由他强，清风拂山岗。他横任他横，明月照大江。”美团还在下方写到：“若被人诽谤，切切不可分辩。我常见有人被诽谤，就分辩解释，多受了亏。”</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/20b480da6cc695d3ae53dfba4ffbfede\" tg-width=\"861\" tg-height=\"325\"/></p><p style=\"text-align: start;\">此前，美团官方帐号“小团有话说”发布《关于已辟谣谣言被某平台再度利用的说明》。</p><p style=\"text-align: start;\">美团在文中表示，全球没有任何平台有动力、有能力去约束外卖骑手的接单选择。自外卖行业诞生以来，美团、饿了么、百度、抖音等参与者均未限制骑手多平台工作。</p><p style=\"text-align: start;\">美团称，美团从未限制骑手在饿了么上接单（单量为某平台数倍），未要求骑手不跑闪送、顺丰等其他即时配送平台，同样更没有任何理由对某平台进行任何限制。目前，行业里限制骑手选择的企业只有某平台自己。某平台明确要求全职骑手不准跑其他平台订单。</p><p style=\"text-align: start;\">美团发文还提到，某平台配送延误问题主要是自身原因，某平台给骑手设置了较短配送时长，且据骑手反馈，在各平台探索取消超时罚款时，某平台对超时骑手进行了大额罚款，甚至经常出现扣罚骑手400元的情况。</p><p style=\"text-align: start;\">“某平台配送时限过短、全职骑手数量不足、兼职骑手被区别对待，加上罚款严重，将不同地址非顺路多笔订单打包捆绑要求配送等问题，导致骑手不愿加入，延误问题高发，用户体验受损。”美团称。</p><p style=\"text-align: start;\">与此同时，美团文章内容提到，4月18日以来，某平台通知商户出资承担消费者的补贴（30%-50%比例不等），否则会被降序。按此测算，商户每单最高要掏10块钱来给某平台做补贴。因此，不少商户主动选择减少某平台订单。</p></body></html>","source":"sina_tech","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美团再发声：与其造谣引流不如兑现承诺，此前辟谣“二选一”</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美团再发声：与其造谣引流不如兑现承诺，此前辟谣“二选一”\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-21 19:22 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/tech/2025-04-21/doc-inetxsmv6214183.shtml><strong>新浪科技</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>周一晚间消息，美团官方公众号今晚发声：“与其造谣引流，不如兑现承诺”，并配文：“他强由他强，清风拂山岗。他横任他横，明月照大江。”美团还在下方写到：“若被人诽谤，切切不可分辩。我常见有人被诽谤，就分辩解释，多受了亏。”此前，美团官方帐号“小团有话说”发布《关于已辟谣谣言被某平台再度利用的说明》。美团在文中表示，全球没有任何平台有动力、有能力去约束外卖骑手的接单选择。自外卖行业诞生以来，美团、饿了么...</p>\n\n<a href=\"https://finance.sina.com.cn/tech/2025-04-21/doc-inetxsmv6214183.shtml\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/ac8ba300095aa1d7469e63485ef42d4c","relate_stocks":{"03690":"美团-W"},"source_url":"https://finance.sina.com.cn/tech/2025-04-21/doc-inetxsmv6214183.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1110612549","content_text":"周一晚间消息，美团官方公众号今晚发声：“与其造谣引流，不如兑现承诺”，并配文：“他强由他强，清风拂山岗。他横任他横，明月照大江。”美团还在下方写到：“若被人诽谤，切切不可分辩。我常见有人被诽谤，就分辩解释，多受了亏。”此前，美团官方帐号“小团有话说”发布《关于已辟谣谣言被某平台再度利用的说明》。美团在文中表示，全球没有任何平台有动力、有能力去约束外卖骑手的接单选择。自外卖行业诞生以来，美团、饿了么、百度、抖音等参与者均未限制骑手多平台工作。美团称，美团从未限制骑手在饿了么上接单（单量为某平台数倍），未要求骑手不跑闪送、顺丰等其他即时配送平台，同样更没有任何理由对某平台进行任何限制。目前，行业里限制骑手选择的企业只有某平台自己。某平台明确要求全职骑手不准跑其他平台订单。美团发文还提到，某平台配送延误问题主要是自身原因，某平台给骑手设置了较短配送时长，且据骑手反馈，在各平台探索取消超时罚款时，某平台对超时骑手进行了大额罚款，甚至经常出现扣罚骑手400元的情况。“某平台配送时限过短、全职骑手数量不足、兼职骑手被区别对待，加上罚款严重，将不同地址非顺路多笔订单打包捆绑要求配送等问题，导致骑手不愿加入，延误问题高发，用户体验受损。”美团称。与此同时，美团文章内容提到，4月18日以来，某平台通知商户出资承担消费者的补贴（30%-50%比例不等），否则会被降序。按此测算，商户每单最高要掏10块钱来给某平台做补贴。因此，不少商户主动选择减少某平台订单。","news_type":1,"symbols_score_info":{"03690":1.1}},"isVote":1,"tweetType":1,"viewCount":988,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":414821582607008,"gmtCreate":1742293413842,"gmtModify":1742293415987,"author":{"id":"3506509089469805","authorId":"3506509089469805","name":"大耳朵Ears","avatar":"https://static.tigerbbs.com/b2f85cc68cf636aa2ce111d8b2ebe575","crmLevel":7,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3506509089469805","authorIdStr":"3506509089469805"},"themes":[],"htmlText":"短期受政治因素扰动风险，长期绝佳机会","listText":"短期受政治因素扰动风险，长期绝佳机会","text":"短期受政治因素扰动风险，长期绝佳机会","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/414821582607008","isVote":1,"tweetType":1,"viewCount":1355,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":412676032799040,"gmtCreate":1741789962367,"gmtModify":1741789964599,"author":{"id":"3506509089469805","authorId":"3506509089469805","name":"大耳朵Ears","avatar":"https://static.tigerbbs.com/b2f85cc68cf636aa2ce111d8b2ebe575","crmLevel":7,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3506509089469805","authorIdStr":"3506509089469805"},"themes":[],"htmlText":"绝对的好机会","listText":"绝对的好机会","text":"绝对的好机会","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/412676032799040","isVote":1,"tweetType":1,"viewCount":1122,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"followers","isTTM":false}